Navigation Links
VIVUS Announces Date of FDA Advisory Committee Review of Qnexa for the Treatment of Obesity
Date:12/23/2011

MOUNTAIN VIEW, Calif., Dec. 23, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) is scheduled to review the Company's New Drug Application (NDA) for Qnexa for the treatment of obesity on February 22, 2012. VIVUS resubmitted the NDA on October 17, 2011 seeking approval to market Qnexa in the United States. The FDA accepted the NDA for review on November 3, 2011. The target date for the FDA to complete its review of the Qnexa NDA is April 17, 2012. 

About QnexaQnexa [kyoo-nek-suh] is an investigational drug candidate being developed to address weight loss, type 2 diabetes and obstructive sleep apnea. Qnexa is a once-a-day, proprietary, oral, controlled-release formulation of low-dose phentermine and topiramate, which is designed to decrease appetite and increase satiety (the sense of feeling full), the two main mechanisms that impact eating behavior. In phase 2 and 3 clinical data to date, patients taking Qnexa have demonstrated statistically significant weight loss, glycemic control, and improvement in cardiovascular risk factors, when used in combination with a diet and lifestyle modification program.

About VIVUS VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health.  The company's lead investigational product in clinical development, Qnexa, has completed phase 3 clinical trials for the treatment of obesity and is currently being considered for approval by US and EU regulators.  VIVUS received a Complete Response Letter, or CRL, to the initial Qnexa NDA on October 28, 2010.  We resubmitted the Qnexa NDA in October 2011, with an FDA action date of April 17, 2012.  Qnexa is also in phase 2 clinical development for the treatment of type
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Results From Phase 3 EQUATE Trial of VIVUS Qnexa Highlighted at European Congress on Obesity
2. VIVUS Initiates Open Label Safety Study of Avanafil for Erectile Dysfunction
3. Data on VIVUS Qnexa to be Featured at European Association for the Study of Diabetes Annual Meeting
4. VIVUS Announces Promotion of Peter Tam to President
5. VIVUS to Present at Lazard Capital Markets Healthcare Conference
6. VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity
7. VIVUS to Host Conference Call and Webcast Discussion of Avanafil Phase 3 Results
8. VIVUS Announces Sale of MUSE Assets to Meda
9. FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA®
10. VIVUS Reports Third Quarter and First Nine Months 2010 Financial Results
11. VIVUS to Present at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... YORK , Sept. 2, 2015   About ... the most common laboratory technologies that is used for ... antibodies in solution. ELISA test uses various types of ... phosphatases and the result is detected by photometry or ... the treatment of various infectious diseases such as HIV, ...
(Date:9/2/2015)... Calif. , Sept. 2, 2015 STAAR Surgical ... marketer of implantable lenses and delivery systems for the eye, ... William P. Wall to the Company,s Board. ... Capital, a Boston -based investment firm, for ... of the Board of Directors, and chair of the Corporate ...
(Date:9/2/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/275q7t/inhaled_drug ) has announced ... UK - November 19-20, 2015)" conference to their ... cover industry case studies, regulatory updates, latest therapies and ... Steven Nichols , OINP Specialist Consultant and ... Companies participating include: - Aptar Pharma ...
Breaking Medicine Technology:Global Enzyme-Linked Immunosorbent Assay (Elisa) Testing Market 2015-2019 2Global Enzyme-Linked Immunosorbent Assay (Elisa) Testing Market 2015-2019 3William P. Wall Appointed to STAAR Surgical Board of Directors 2
(Date:9/3/2015)... ... September 03, 2015 , ... Representatives with ... at the highly anticipated Mississippi Gulf Babypalooza on September 19, 2015. , “We ... from Gulfport, Biloxi, and beyond. We will be discussing setting up college funds, ...
(Date:9/3/2015)... ... September 03, 2015 , ... At Renew Man™, we have seen an ... health care model, where the primary care physician dictates and the patient obeys. Instead, ... educated about their health issues and empowered to choose their own treatment options. , ...
(Date:9/3/2015)... ... September 03, 2015 , ... About 220,800 new cases of prostate cancer are reported each year, ... diagnosed with prostate cancer during their lifetime. While only one man in 10,000 will typically ... by age 65, according to the American Cancer Society. , Prostate ...
(Date:9/3/2015)... ... September 03, 2015 , ... James Earl Jones will ... wellness. In this episode, James Earl Jones will introduce a segment that discusses why ... workplace and how workplace wellness can be fostered in any working environment. , Employers ...
(Date:9/3/2015)... FLORIDA (PRWEB) , ... September 03, 2015 , ... ... of the highest-regarded health professionals out there. His perspective on internal medicine keeps patients ... stay happy and healthy is important regardless of the season, but even more so ...
Breaking Medicine News(10 mins):Health News:State Farm Agent EJ Roberts to Help Expecting Mothers at the Mississippi Gulf Babypalooza 2Health News:Men Dissatisfied with the Primary Care Physician’s Approach to Andropause Are Turning to Renew Man™ 2Health News:Men Dissatisfied with the Primary Care Physician’s Approach to Andropause Are Turning to Renew Man™ 3Health News:Noted Santa Rosa Urologist Dr. Michael Lazar Provides Insights on Prostate Cancer Treatments in Recognition of Prostate Cancer Awareness Month 2Health News:Noted Santa Rosa Urologist Dr. Michael Lazar Provides Insights on Prostate Cancer Treatments in Recognition of Prostate Cancer Awareness Month 3Health News:James Earl Jones Hosts a New "Voices In America" Piece on Making the Workplace Healthier 2Health News:Doctor Kayode Sotonwa Highlights Expert Tips for Staying in Shape This Fall 2
... Eli Lilly and Company (NYSE: LLY ) today declared a ... outstanding common stock. This is the same dividend as was paid ... rate for 2009 of $1.96 per share. , , The ... close of business on August 15, 2009. , , About Lilly ...
... blames physician misdiagnosis as the likely cause of apparent uptick ... A newly released study in the June 2009 British Journal ... the eastern United Kingdom has concluded that the much-hyped melanoma ... The study attributed the increase in melanoma diagnoses to heightened ...
... Now there,s a new reason for the,weight-conscious to drink fat ... the July issue of the American Journal of Clinical,Nutrition. Researchers ... helped increase satiety, or a feeling of fullness, and lead ... a fruit drink. The,milk drinkers ate about 50 fewer calories ...
... Personalized Medicine Meeting Elicits Varying Perspectives , , WASHINGTON, ... to regulate genetic testing is problematic, according to a recent ... of the attendees at a colloquium on personalized medicine, sponsored ... American Association for the Advancement of Science (AAAS) responded "yes" ...
... to attend field hearing exploring use of Recovery Act funds ... Senator Benjamin L. Cardin (D-MD ), chaired a field hearing ... Entrepreneurship in Rockville, MD, entitled " Missed Opportunities: The ... local and national experts in biotechnology testified about the important ...
... Center,s two camps, Camp Courage in Maple Lake and Courage North ... people with disabilities. , , A recent Muscular Dystrophy camp ... MDA staff) who tested positive for H1N1 flu (also known as ... officials were contacted by the MDA locally three days after the ...
Cached Medicine News:Health News:New Study Says Purported Melanoma Epidemic is Vastly Overstated 2Health News:Drinking Milk in the Morning May Help Stave off Lunchtime Hunger 2Health News:FDA's Current Ability to Regulate Genetic Testing is Problematic, FDLI-AAAS Colloquium Attendees Say 2Health News:FDA's Current Ability to Regulate Genetic Testing is Problematic, FDLI-AAAS Colloquium Attendees Say 3Health News:Cardin Calls on NIH to Utilize Small Businesses for Extramural Research Projects 2Health News:Courage Camps Maintain Summer Camp Schedule for Children and Adults With Disabilities 2
Rapid Test Kit...
... Advanced Vision Information System) is an open ... on a platform designed to communicate and ... network can be expanded in various ways, ... Nidek products but also to fundus cameras ...
... laser photocoagulators includes the OcuLight SL and ... as a single laser source for multiple ... maintenance or special electrical/cooling, and allow easy ... SLx is now available with Tri-Mode capability ...
The simplest, most accurate Ortho-K lens fitting system ever!...
Medicine Products: